NO20052998L - Alfa krystallinsk form av strontiumranelat, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den. - Google Patents

Alfa krystallinsk form av strontiumranelat, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den.

Info

Publication number
NO20052998L
NO20052998L NO20052998A NO20052998A NO20052998L NO 20052998 L NO20052998 L NO 20052998L NO 20052998 A NO20052998 A NO 20052998A NO 20052998 A NO20052998 A NO 20052998A NO 20052998 L NO20052998 L NO 20052998L
Authority
NO
Norway
Prior art keywords
crystalline form
preparation
pharmaceutical compositions
compositions containing
strontium ranelate
Prior art date
Application number
NO20052998A
Other languages
English (en)
Other versions
NO333948B1 (no
NO20052998D0 (no
Inventor
Gerard Damien
Stephane Horvath
Isabelle Demuynck
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34942420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052998(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of NO20052998D0 publication Critical patent/NO20052998D0/no
Publication of NO20052998L publication Critical patent/NO20052998L/no
Publication of NO333948B1 publication Critical patent/NO333948B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Fodder In General (AREA)

Abstract

Alfakrystallinsk form av strontiumranelat med formel (I): kjennetegnet ved dens pulverrøntgendiffraksjonsdiagram og ved et vanninnhold på fra 22 til 24 %. Medikamenter.
NO20052998A 2004-09-30 2005-06-17 Alfakrystallinsk form av strontiumranelat, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den. NO333948B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0410335A FR2875807B1 (fr) 2004-09-30 2004-09-30 Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (3)

Publication Number Publication Date
NO20052998D0 NO20052998D0 (no) 2005-06-17
NO20052998L true NO20052998L (no) 2006-03-31
NO333948B1 NO333948B1 (no) 2013-10-28

Family

ID=34942420

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052998A NO333948B1 (no) 2004-09-30 2005-06-17 Alfakrystallinsk form av strontiumranelat, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den.

Country Status (41)

Country Link
US (2) US7459568B2 (no)
EP (2) EP1944302A1 (no)
JP (2) JP2006104184A (no)
KR (1) KR100816590B1 (no)
CN (1) CN100391956C (no)
AP (1) AP1930A (no)
AR (1) AR049395A1 (no)
AT (1) ATE411308T1 (no)
AU (1) AU2005202718B2 (no)
BR (1) BRPI0502228A (no)
CA (1) CA2508824C (no)
CO (1) CO5710195A1 (no)
CR (1) CR7876A (no)
CY (1) CY1108797T1 (no)
DE (1) DE602005010359D1 (no)
DK (1) DK1642897T3 (no)
EA (1) EA008474B1 (no)
EC (1) ECSP055859A (no)
ES (1) ES2314593T3 (no)
FR (1) FR2875807B1 (no)
GE (1) GEP20074106B (no)
GT (1) GT200500130A (no)
HR (1) HRP20080652T3 (no)
IL (1) IL169237A (no)
MA (1) MA27815A1 (no)
MX (1) MXPA05006407A (no)
NO (1) NO333948B1 (no)
NZ (1) NZ540802A (no)
OA (1) OA13013A (no)
PA (1) PA8638201A1 (no)
PE (1) PE20060364A1 (no)
PL (1) PL1642897T3 (no)
PT (1) PT1642897E (no)
RS (1) RS51110B (no)
SA (1) SA05260168B1 (no)
SG (1) SG121035A1 (no)
SI (1) SI1642897T1 (no)
TW (1) TWI367881B (no)
UA (1) UA80008C2 (no)
WO (1) WO2006035122A1 (no)
ZA (1) ZA200504937B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
US20070292535A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating arthritic and or osteoporitic conditions
US20070292529A1 (en) * 2006-06-19 2007-12-20 Tabbiner Philip S Strontium compositions and methods of treating osteoporotic conditions
CN101206208B (zh) * 2006-12-19 2011-08-10 北京德众万全药物技术开发有限公司 一种用hplc法分析雷尼酸锶原料及其制剂的方法
EP2346846A1 (en) * 2008-09-29 2011-07-27 Ratiopharm GmbH Anhydrate and hydrate forms of strontium ranelate
IT1398542B1 (it) * 2010-03-05 2013-03-01 Chemelectiva S R L Processo per la preparazione di un polimorfo
CN102241663B (zh) * 2010-05-10 2013-02-13 山东方明药业集团股份有限公司 一种雷奈酸锶八水合物的制备方法
WO2012143932A1 (en) * 2011-04-21 2012-10-26 Shilpa Medicare Limited Crystalline strontium ranelate form-s
CZ2011320A3 (cs) 2011-05-30 2012-12-12 Zentiva, K.S. Stabilní krystalická forma X stroncium ranelátu
EP2530068A1 (en) 2011-05-31 2012-12-05 Lacer, S.A. New strontium salts, synthesis and use thereof in the treatment of osteoporosis
WO2013013003A1 (en) 2011-07-21 2013-01-24 Emory University Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation
CN102503931A (zh) * 2011-09-20 2012-06-20 浙江华海药业股份有限公司 一种雷尼酸锶晶形h的制备方法
WO2013113319A1 (en) * 2012-01-31 2013-08-08 Pharmathen S.A. Process for the preparation of strontium ranelate, intermediate or hydrates thereof
EP2641905A1 (en) 2012-03-23 2013-09-25 Urquima S.A. Solid forms of strontium ranelate and processes for their preparation
US8569514B1 (en) 2012-05-17 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of strontium ranelate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2651497B1 (fr) * 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
PL181304B1 (pl) 1994-07-22 2001-07-31 Lilly Co Eli Preparat farmaceutyczny do hamowania zmniejszania masy kosci PL PL PL PL PL PL PL PL PL PL
FR2749759B1 (fr) * 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
DE19642451A1 (de) 1996-10-15 1998-04-16 Merck Patent Gmbh Aminothiophencarbonsäureamide
ES2272781T5 (es) * 2001-10-03 2010-04-06 Teva Pharmaceutical Industries Ltd. Preparacion de levofloxacino hemihidratado.
CA2471144C (en) * 2002-01-09 2011-06-07 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
WO2004012739A1 (en) * 2002-08-06 2004-02-12 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
FR2844797B1 (fr) 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2844795B1 (fr) * 2002-09-24 2004-10-22 Servier Lab Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates
FR2844796A1 (fr) 2002-09-24 2004-03-26 Servier Lab Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
EA200500842A1 (ru) 2006-04-28
MA27815A1 (fr) 2006-04-03
SI1642897T1 (sl) 2009-02-28
KR20060049966A (ko) 2006-05-19
EP1642897B1 (fr) 2008-10-15
PT1642897E (pt) 2008-11-27
NZ540802A (en) 2006-11-30
CA2508824C (fr) 2009-03-24
NO333948B1 (no) 2013-10-28
ES2314593T3 (es) 2009-03-16
PA8638201A1 (es) 2006-05-16
DE602005010359D1 (de) 2008-11-27
FR2875807B1 (fr) 2006-11-17
CO5710195A1 (es) 2006-12-29
ZA200504937B (en) 2006-04-26
CN100391956C (zh) 2008-06-04
AP1930A (en) 2008-12-15
NO20052998D0 (no) 2005-06-17
AU2005202718B2 (en) 2010-09-16
AR049395A1 (es) 2006-07-26
ECSP055859A (es) 2006-09-18
US7745482B2 (en) 2010-06-29
SG121035A1 (en) 2006-04-26
EP1642897B9 (fr) 2009-08-12
BRPI0502228A (pt) 2006-05-09
OA13013A (fr) 2006-11-10
HK1086260A1 (zh) 2006-09-15
TWI367881B (en) 2012-07-11
US7459568B2 (en) 2008-12-02
SA05260168B1 (ar) 2009-02-25
ATE411308T1 (de) 2008-10-15
GT200500130A (es) 2005-12-20
CY1108797T1 (el) 2014-04-09
MXPA05006407A (es) 2006-04-05
UA80008C2 (uk) 2007-08-10
AU2005202718A1 (en) 2006-04-13
PL1642897T3 (pl) 2009-04-30
EP1642897A1 (fr) 2006-04-05
CN1754878A (zh) 2006-04-05
IL169237A (en) 2010-12-30
JP2010132669A (ja) 2010-06-17
WO2006035122A1 (fr) 2006-04-06
CA2508824A1 (fr) 2006-03-30
AP2005003323A0 (en) 2005-06-30
CR7876A (es) 2007-12-10
US20060069271A1 (en) 2006-03-30
FR2875807A1 (fr) 2006-03-31
JP2006104184A (ja) 2006-04-20
DK1642897T3 (da) 2009-01-26
EA008474B1 (ru) 2007-06-29
US20080312314A1 (en) 2008-12-18
RS51110B (sr) 2010-10-31
GEP20074106B (en) 2007-05-10
PE20060364A1 (es) 2006-06-17
HRP20080652T3 (en) 2009-01-31
TW200610758A (en) 2006-04-01
EP1944302A1 (fr) 2008-07-16
KR100816590B1 (ko) 2008-03-24

Similar Documents

Publication Publication Date Title
NO20063517L (no) Ny krystallinsk form v av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063518L (no) Ny krystallinsk form IV av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20052998L (no) Alfa krystallinsk form av strontiumranelat, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den.
NO20060948L (no) Á-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063516L (no) Ny krystallinsk form III av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20060946L (no) β-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20064588L (no) Delta d-krystallinsk form av ivabradin-hydroklorid, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende den
JO3178B1 (ar) النموذج السادس البلوري الجديد من مركب الاغوميلاتين وطريقة تحضيره وتحضير المركبات الصيدلانية المحتوية عليه
RU2009131727A (ru) Макроциклические полиморфы, композиции, содержащие такие полиморфы, и способы их применения и получения
EA201101695A1 (ru) Усовершенствованный способ синтеза пирфенидона
TW200640874A (en) &bgr d-crystallind form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
NO20082265L (no) Dispergerbare tabletter som innbefatter deferasirox
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
ATE495747T1 (de) Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
TW200640871A (en) γ d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
MY151035A (en) ? crystalline form of the arginine salt of perindopril, a process for its preparation and pharmaceutical compositions containing it
MX2022005722A (es) Metodo para preparar compuesto derivado heterociclico, composicion que contiene el mismo compuesto, e hidrato del mismo compuesto.
NO20092149L (no) Spiro-piperidinderivater
MY157492A (en) Pharmaceutical composition 271
BR0306701A (pt) Composto, sal do composto, sal de cálcio, método de preparação de um sal, composição farmacêutica, método de preparação de uma composição, e, uso de um sal
ATE454383T1 (de) Neue verbindungen, deren verwendung und herstellung
NO20092264L (no) Spiro-piperidinderivater
NO20075237L (no) Forbedret fremgangsmate for rensing av oerindorpril
EA200900936A1 (ru) Аморфные и кристаллические формы ривастигмина гидротартрата
MY138209A (en) New (y) crystalline form of perindopril tert-butylamine salt, a process for its preparation and pharmaceutical compositions containing it.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees